Absci Quick Ratio (ABSI) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Absci Corp  (NASDAQ: ABSI)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Absci's Quick Ratio

ABSI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 8.7 above Absci Corp average.

Within Medical Laboratories industry 4 other companies have achieved higher Quick Ratio than Absci in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 457, from total ranking in the second quarter 2026 at 546.

Explain Quick Ratio?
How much Cash & cash equivalents ABSI´s has?
What are ABSI´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ABSI/financial-strength
https://api.csimarket.com/api/v1/companies/ABSI/fundamentals
https://api.csimarket.com/api/v1/companies/ABSI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ABSI Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -25.73 %
Y / Y Cash & cash equivalent Change 13.94 %
Quick Ratio MRQ 8.7
ABSI's Total Ranking # 457
Seq. Current Liabilities Change 0.4 %
Seq. Cash & cash equivalent Change -13.63 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Laboratories Industry # 5
Healthcare Sector # 160
Overall Market # 457


Quick Ratio Statistics
High Average Low
15.23 5.46 0.49
(Dec 31 2020)   (Mar 31 2023)




Financial Statements
Absci's Current Liabilities $ 20 Millions Visit ABSI's Balance sheet
Absci's Cash & cash equivalent $ 174 Millions Visit ABSI's Balance sheet
Source of ABSI's Sales Visit ABSI's Sales by Geography


Cumulative Absci's Quick Ratio

ABSI's Quick Ratio for the trailling 12 Months

ABSI Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -30.5 %
Y / Y Cash & cash equivalent TTM Growth 84.29 %
Quick Ratio TTM 8.29
Total Ranking TTM # 1594
Seq. Current Liabilities TTM Growth -8.16 %
Seq. Cash & cash equivalent TTM Growth 3.41 %


On the trailing twelve months basis ABSI Cash & cash equivalent increased by 13.94 % in Q3 2026 year on year, while Current Liabilities rose to $20 millions, this led to increase in in Absci's Quick Ratio to 8.29, above ABSI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 33 other companies have achieved higher Quick Ratio than Absci. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2754 to 3862.

Explain Quick Ratio?
How much Cash & cash equivalents ABSI´s has?
What are ABSI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Laboratories Industry # 34
Healthcare Sector # 886
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
7 2.91 0.73
(Jun 30 2022)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Aclarion Inc   13.58 $ 14.188  Millions$ 1.044  Millions
Celcuity Inc   12.38 $ 642.703  Millions$ 51.925  Millions
Miragen Therapeutics Inc   11.70 $ 955.206  Millions$ 81.673  Millions
Billiontoone Inc   9.26 $ 561.512  Millions$ 60.637  Millions
Absci Corp  8.70 $ 173.729  Millions$ 19.958  Millions
Maxcyte inc   6.36 $ 101.280  Millions$ 15.916  Millions
Personalis Inc   5.17 $ 254.841  Millions$ 49.274  Millions
Veracyte Inc   4.40 $ 370.532  Millions$ 84.209  Millions
Castle Biosciences Inc   4.11 $ 277.665  Millions$ 67.612  Millions
Fulgent Genetics Inc   4.07 $ 292.739  Millions$ 71.877  Millions
Omniab Inc   3.81 $ 64.210  Millions$ 16.853  Millions
Guardant Health Inc   2.75 $ 1,026.848  Millions$ 373.165  Millions
Incyte Corporation  2.68 $ 3,854.572  Millions$ 1,437.818  Millions
Exagen Inc   2.14 $ 28.092  Millions$ 13.100  Millions
Biodesix Inc   1.99 $ 28.409  Millions$ 14.248  Millions
Caredx Inc   1.80 $ 250.480  Millions$ 138.975  Millions
Butterfly Network Inc   1.80 $ 122.301  Millions$ 67.987  Millions
Sera Prognostics Inc   1.80 $ 44.089  Millions$ 24.527  Millions

Date modified: 2026-11-13T05:14:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.